Growth Metrics

Eli Lilly (LLY) Shareholder's Equity Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 117.29%
Dec 31, 2025 563.12%
Sep 30, 2025 96.20%
Jun 30, 2025 76.53%
Mar 31, 2025 19.77%
Dec 31, 2024 27.17%
Sep 30, 2024 25.00%
Jun 30, 2024 -79.50%
Mar 31, 2024 -12.58%
Dec 31, 2023 22.59%
Sep 30, 2023 80.99%
Jun 30, 2023 -72.71%
Mar 31, 2023 -89.29%
Dec 31, 2022 -76.12%
Sep 30, 2022 -38.38%
Jun 30, 2022 -38.49%
Mar 31, 2022 -3.48%
Dec 31, 2021 -324.44%
Sep 30, 2021 -692.72%
Jun 30, 2021 69.05%
Mar 31, 2021 11.00%
Dec 31, 2020 -202.67%
Sep 30, 2020 -75.85%
Jun 30, 2020 30.03%
Mar 31, 2020 51.97%
Dec 31, 2019 223.00%
Sep 30, 2019 62.72%
Jun 30, 2019 462.07%
Mar 31, 2019 -52.03%
Dec 31, 2018 -70.88%
Sep 30, 2018 -91.61%
Jun 30, 2018 -30.16%
Mar 31, 2018 -31.73%
Dec 31, 2017 -26.31%
Sep 30, 2017 -27.41%
Jun 30, 2017 -29.42%
Mar 31, 2017 -31.50%
Dec 31, 2016 -26.24%
Sep 30, 2016 -29.45%
Jun 30, 2016 -86.58%
Mar 31, 2016 -27.50%
Dec 31, 2015 -89.12%
Sep 30, 2015 -1.72%
Jun 30, 2015 0.92%
Mar 31, 2015 0.28%
Dec 31, 2014 4.32%
Sep 30, 2014 5.48%
Jun 30, 2014 8.00%
Mar 31, 2014 9.59%
Dec 31, 2013 12.39%
Sep 30, 2013 10.85%
Jun 30, 2013 14.18%
Mar 31, 2013 12.65%
Dec 31, 2012 431.21%
Sep 30, 2012 17.47%
Jun 30, 2012 18.68%